Max Levin
Impact in
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
- Biochemistry top 5%
Papers in
-
- Angiogenesis and VEGF in Cancer 4
- Melanoma and MAPK Pathways 4
- Congenital heart defects research 3
- Oncology 10
- Cancer Immunotherapy and Biomarkers 7
- Co-authors
- Tom Björnheden (4 shared papers)Olov Wiklund (5 shared papers)Lillemor Mattsson Hultén (4 shared papers)Jan Borén (15 shared papers)Marcus Ståhlman (4 shared papers)Lars Ny (13 shared papers)Jens Nielsen (3 shared papers)Angelo Limeta (2 shared papers)
- Journals
- PLoS ONE (4 papers)Arteriosclerosis Thrombosis and Vascular Biology (4 papers)Atherosclerosis (2 papers)Journal of Clinical Oncology (2 papers)Novartis Foundation symposium (2 papers)
- Partner nations
- SwedenUnited StatesGermany
In The Last Decade
Max Levin
55 papers receiving 1.8k citations
Peers
Comparison fields: 5 of 107
- Cancer Research 254
- Biochemistry 107
- Immunology 288
- Ophthalmology 96
- Molecular Biology 812
Countries citing papers authored by Max Levin
This map shows the geographic impact of Max Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Levin more than expected).
Fields of papers citing papers by Max Levin
This network shows the impact of papers produced by Max Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Levin. The network helps show where Max Levin may publish in the future.
Co-authors
The 25 scholars most cited alongside Max Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1999 | 239 | |
| 2 | 2016 | 220 | |
| 3 | 2013 | 139 | |
| 4 | 2021 | 125 | |
| 5 | 2020 | 108 | |
| 6 | 2009 | 84 | |
| 7 | 2006 | 81 | |
| 8 | 2000 | 65 | |
| 9 | 2004 | 58 | |
| 10 | 2019 | 54 | |
| 11 | 2012 | 50 | |
| 12 | 2019 | 43 | |
| 13 | 2007 | 41 | |
| 14 | 2012 | 38 | |
| 15 | 2019 | 37 | |
| 16 | 2015 | 34 | |
| 17 | 2018 | 33 | |
| 18 | 1976 | 33 | |
| 19 | 2005 | 29 | |
| 20 | 2019 | 27 |
About Max Levin
Max Levin is a scholar working on Molecular Biology, Oncology, Immunology, Ophthalmology and Cancer Research, having authored 57 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Ocular Oncology and Treatments (6 papers), Angiogenesis and VEGF in Cancer (4 papers), Immunotherapy and Immune Responses (4 papers), Melanoma and MAPK Pathways (4 papers), Congenital heart defects research (3 papers), Lipid metabolism and biosynthesis (3 papers) and Protease and Inhibitor Mechanisms (3 papers). The work is most often cited by research in Cancer Research (254 citations), Biochemistry (107 citations), Immunology (288 citations), Ophthalmology (96 citations) and Molecular Biology (812 citations). Max Levin has collaborated with scholars based in Sweden, United States and Germany. Frequent co-authors include Tom Björnheden, Olov Wiklund, Lillemor Mattsson Hultén, Jan Borén, Marcus Ståhlman, Lars Ny, Jens Nielsen, Angelo Limeta, Olli Leppänen and Francesco Gatto. Their work appears in journals such as PLoS ONE, Arteriosclerosis Thrombosis and Vascular Biology, Atherosclerosis, Journal of Clinical Oncology and Novartis Foundation symposium.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.